# Melanotan II adverse-effect reports

Canonical: https://europeanpeptideshop.com/blog/melanotan-2-side-effects/

Explore the catalogue and research library. Ordering and shipping have not opened yet.

Compound research · 8 November 2026 · 2 min read · By [European Peptide Shop](https://europeanpeptideshop.com/about/)

### On this page

Published reports about Melanotan II include small early human studies, individual case reports and regulator warnings about unregulated products. These sources answer different questions. They do not establish how frequently an event occurs across all products marketed under the name.

A useful reading separates what happened, how the material was identified and what the authors could conclude about causality. The absence of a reported event in a small study is not proof that the event cannot occur.

## What case reports can establish

A case report documents an observation in one person or a small group. It can identify a concern worth investigating, but it usually cannot estimate a population-level risk. Unknown product composition, other exposures and incomplete information can limit interpretation.

Reports associated with unregulated melanotan products should therefore retain the authors' description of the material. Do not silently recast an internet product as a verified laboratory reference standard or assume that a label proves its contents.

## Product composition is a separate question

In an August 2026 advisory, Australia's TGA reported inconsistent Melanotan II content across five tested nasal-spray bottles from a named product line. This is a finding about the seized products in that investigation. It is not an analytical result for an EPS vial.

The example illustrates why the biological question and the analytical question need separate evidence. A report of symptoms does not establish chemical identity; a chemical measurement does not establish suitability for use in people.

## Keep the evidence categories visible

Source | Useful information | Main limit

Small clinical study | Observations in its selected participants | Limited size and study conditions

Case report | A documented event and clinical history | Cannot establish event frequency

Product investigation | Results for tested samples | Does not cover all products or batches

Research COA | The tests and sample stated on the report | Does not establish a clinical safety profile

For the molecular background, read [Melanotan II research](https://europeanpeptideshop.com/blog/melanotan-2/) and the [comparison with Melanotan I](https://europeanpeptideshop.com/blog/melanotan-i-vs-ii/). The EMA assessment of Scenesse concerns the authorised afamelanotide product, a separate molecule and formulation context; it is not an authorisation for Melanotan II.

Anyone experiencing symptoms after using an unregulated product should seek medical advice. EPS materials are listed for in-vitro laboratory research, and no EPS batch certificate is currently published.

## Laboratory research only

Materials listed on this site are supplied for in-vitro laboratory research and are not for use in or on humans or animals. They are not medicines. This article summarises published work and gives no dosing, administration, treatment or in-vivo guidance. Findings from a study apply to the material and conditions of that study, and they say nothing about any product listed here.

## References

- [TGA: Melanotan II products found to contain inconsistent amounts, 17 August 2026](https://www.tga.gov.au/safety/safety-monitoring-and-information/safety-alerts/melanotan-ii-tanning-peptide-products-found-be-inconsistently-dosed)

- [EMA: Scenesse assessment](https://www.ema.europa.eu/en/medicines/human/EPAR/scenesse)

## More articles

Comparisons · 3 min read

## [Melanotan I versus melanotan II](https://europeanpeptideshop.com/blog/melanotan-i-vs-ii/)

One is linear, selective and a licensed medicine under another name. The other is cyclic, non-selective and never licensed. The structural and regulatory.

8 November 2026

Compound research · 3 min read

## [Melanotan II research explained](https://europeanpeptideshop.com/blog/melanotan-2/)

What Melanotan II is, how it relates to alpha-MSH, which melanocortin receptors it binds, and why it has never been a licensed medicine anywhere.

8 November 2026

Compound research · 4 min read

## [BPC-157 research explained](https://europeanpeptideshop.com/blog/bpc-157-research/)

A plain-English guide to BPC-157: what the studies measured, what a 10mg vial label means, and how to distinguish evidence from unsupported claims.

8 November 2026